NNZ 2591

国际站：NNZ 2591

CAS：847952-38-9

品牌：MedChemExpress (MCE)

存储条件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性：NNZ 2591 是环状甘氨酸脯氨酸 (cGP) 小肽的合成类似物。NNZ 2591 具有口服活性并能穿过血脑屏障。NNZ 2591 在缺血性脑损伤后显示出神经保护作用。NNZ 2591 改善帕金森病大鼠模型的运动功能。NNZ 2591 具有研究缺血性脑损伤和天使综合征的潜力。

体内：NNZ 2591 (30 mg/kg; p.o.) prevented scopolamine-induced memory impairment in rats[1]. NNZ 2591 (2, 20, 100 ng/rat; i.c.v.) shows neuroprotection in rats[2]. NNZ 2591 (3 mg/kg; s.c.; daily for 5 days) completely preventes brain damage and significantly reduces the L/R ratio of time taken to touch to the patch at 5 d after injury in rats[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 4 months, male young adult Wistar rats[1]. Dosage: 30 mg/kg Administration: P.o.; 10 min after the (scopolamine) i.p. administration. Result: Significantly reduced the number of M2AchR positive neurons, significantly reduced the density of synaptophysin in the CA3 and CA4 sub-regions, and altered TH terminal staining in the striatum. Animal Model: 280-310 g adult male Wistar rats[2]. Dosage: 2, 20, 100 ng/rat Administration: I.c.v.; 2 h after HI injury Result: Reduced overall tissue damage in the sub-regions of the hippocampus, DG, cerebral cortex and the striatum. Animal Model: 280-310 g adult male Wistar rats[2]. Dosage: 3 mg/kg Administration: S.c.; daily for 5 days Result: Significantly reduced the median of tissue damage scores in the CA1-2, CA3 and CA4 sub-regions of the hippocampus, the DG.

参考文献：[1]. Guan J, et al. NNZ-2591, a novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat. Behav Brain Res. 2010 Jul 11;210(2):221-8.[2]. Guan J, et al. Peripheral administration of a novel diketopiperazine, NNZ 2591, prevents brain injury and improves somatosensory-motor function following hypoxia-ischemia in adult rats. Neuropharmacology. 2007 Nov;53(6):749-62.[3]. Copping NA, et al. Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman Syndrome. Neurotherapeutics. 2021 Jul;18(3):1535-1547.